"new-vaccine"

Another study discovered that SAGPs are highly expressed in glial cells in Alzheimer's patients.

Moderna, whose results stem from a clinical trial of more than 30,000 participants, expects to have approximately 20 million doses ready to ship in the United States by year-end.